CD8+chimeric antigen receptor T cells manufactured in absence of CD4+cells exhibit hypofunctional phenotype

Author:

Lee Sang Yun,Lee Dong Hoon,Sun Wei,Cervantes-Contreras Francisco,Basom Ryan SORCID,Wu Feinan,Liu Si,Rai Richa,Mirzaei Hamid R,O’Steen Shyril,Green Damian J,Shadman Mazyar,Till Brian GORCID

Abstract

BackgroundCell culture conditions during manufacturing can impact the clinical efficacy of chimeric antigen receptor (CAR) T cell products. Production methods have not been standardized because the optimal approach remains unknown. Separate CD4+and CD8+cultures offer a potential advantage but complicate manufacturing and may affect cell expansion and function. In a phase 1/2 clinical trial, we observed poor expansion of separate CD8+cell cultures and hypothesized that coculture of CD4+cells and CD8+cells at a defined ratio at culture initiation would enhance CD8+cell expansion and simplify manufacturing.MethodsWe generated CAR T cells either as separate CD4+and CD8+cells, or as combined cultures mixed in defined CD4:CD8 ratios at culture initiation. We assessed CAR T cell expansion, phenotype, function, gene expression, and in vivo activity of CAR T cells and compared these between separately expanded or mixed CAR T cell cultures.ResultsWe found that the coculture of CD8+CAR T cells with CD4+cells markedly improves CD8+cell expansion, and further discovered that CD8+cells cultured in isolation exhibit a hypofunctional phenotype and transcriptional signature compared with those in mixed cultures with CD4+cells. Cocultured CAR T cells also confer superior antitumor activity in vivo compared with separately expanded cells. The positive impact of CD4+cells on CD8+cells was mediated through both cytokines and direct cell contact, including CD40L-CD40 and CD70-CD27 interactions.ConclusionsOur data indicate that CD4+cell help during cell culture maintains robust CD8+CAR T cell function, with implications for clinical cell manufacturing.

Funder

NIH

Mustang Bio

Fred Hutchinson Cancer Center

Kleberg Foundation

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3